GURUFOCUS.COM » STOCK LIST » USA » NAS » Atara Biotherapeutics Inc (NAS:ATRA) » Definitions » ROA %
Switch to:

Atara Biotherapeutics ROA %

: 17.73% (As of Jun. 2022)
View and export this data going back to 2014. Start your Free Trial

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Atara Biotherapeutics's annualized Net Income for the quarter that ended in Jun. 2022 was $73.86 Mil. Atara Biotherapeutics's average Total Assets over the quarter that ended in Jun. 2022 was $416.70 Mil. Therefore, Atara Biotherapeutics's annualized ROA % for the quarter that ended in Jun. 2022 was 17.73%.

The historical rank and industry rank for Atara Biotherapeutics's ROA % or its related term are showing as below:

ATRA' s ROA % Range Over the Past 10 Years
Min: -79.2   Med: -49.61   Max: -26.55
Current: -56.07

During the past 10 years, Atara Biotherapeutics's highest ROA % was -26.55%. The lowest was -79.20%. And the median was -49.61%.

ATRA's ROA % is ranked worse than
73.23% of 1569 companies
in the Biotechnology industry
Industry Median: -32.17 vs ATRA: -56.07

Atara Biotherapeutics ROA % Historical Data

The historical data trend for Atara Biotherapeutics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROA %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.61 -75.69 -79.20 -65.86 -64.41

Atara Biotherapeutics Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
ROA % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -67.96 -74.70 -81.35 -81.45 17.73

Competitive Comparison

For the Biotechnology subindustry, Atara Biotherapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Atara Biotherapeutics ROA % Distribution

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's ROA % distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's ROA % falls into.



Atara Biotherapeutics ROA % Calculation

Atara Biotherapeutics's annualized ROA % for the fiscal year that ended in Dec. 2021 is calculated as:

ROA %=Net Income (A: Dec. 2021 )/( (Total Assets (A: Dec. 2020 )+Total Assets (A: Dec. 2021 ))/ count )
=-340.141/( (588.12+468.127)/ 2 )
=-340.141/528.1235
=-64.41 %

Atara Biotherapeutics's annualized ROA % for the quarter that ended in Jun. 2022 is calculated as:

ROA %=Net Income (Q: Jun. 2022 )/( (Total Assets (Q: Mar. 2022 )+Total Assets (Q: Jun. 2022 ))/ count )
=73.864/( (397.28+436.121)/ 2 )
=73.864/416.7005
=17.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2022) net income data. ROA % is displayed in the 30-year financial page.


Atara Biotherapeutics  (NAS:ATRA) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jun. 2022 )
=Net Income/Total Assets
=73.864/416.7005
=(Net Income / Revenue)*(Revenue / Total Assets)
=(73.864 / 206.316)*(206.316 / 416.7005)
=Net Margin %*Asset Turnover
=35.8 %*0.4951
=17.73 %

Note: The Net Income data used here is four times the quarterly (Jun. 2022) net income data. The Revenue data used here is four times the quarterly (Jun. 2022) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Atara Biotherapeutics ROA % Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics Business Description

Atara Biotherapeutics logo
Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T Programs.
Executives
Yarema Kristin officer: Chief Commercial Officer C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO CA 94080
Murugan Amar officer: SVP, GC & Secretary C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD,SUITE 900 SOUTH SAN FRANCISCO CA 94080
Dupont Jakob officer: EVP, Head of R&D C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE REDWOOD CITY CA 94063
Touchon Pascal director, officer: President and CEO C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Koppikar Utpal officer: Chief Financial Officer C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Mallik Ameet director C/O RAFAEL HOLDINGS, INC. 520 BROAD ST NEWARK NJ 07102
Renaud Ronald C Jr director C/O IDENIX PHARMACEUTICALS, INC. 60 HAMPSHIRE STREET CAMBRIDGE MA 02109
Seidenberg Beth C director
Heiden William K director C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Dobmeier Eric director C/O SAETTLE GENETICS INC 21823 30TH DRIVE SE BOTHELL WA 98021
Roncarolo Maria Grazia director C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Gallagher Carol Giltner director C/O ATARA BIOTHERAPEUTICS, INC. 3260 BAYSHORE BOULEVARD BRISBANE CA 94005
Fust Matthew K director C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Baynes Roy D. director C/O RETROPHIN, INC. 12255 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130
Berger Dietmar officer: Global Head of R&D C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080

Atara Biotherapeutics Headlines

From GuruFocus

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)